Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System

    NEXT STORY
    Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System
    PREV STORY
    Revolution Medicines Announces Proposed Public Offering of Common Stock
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe

    Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe ...

    author_avatar
    NASDAQ Market News

    MERIT MEDICAL SYSTEMS DESIGNS AND PRODUCES SAMPLE COLLECTION AND TRANSPORT KIT

    author_avatar
    NASDAQ Market News

    GENFIT Announces New Data to be Presented at AASLD Liver Meeting 2019

    author_avatar
    NASDAQ Market News